Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NGNE NASDAQ:STOK NASDAQ:UPB NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNGNENeurogene$17.45-8.2%$20.70$6.88▼$74.49$249.01M1.58219,609 shs97,415 shsSTOKStoke Therapeutics$23.40-0.3%$16.05$5.35▼$24.60$1.28B1.14815,857 shs854,185 shsUPBUpstream Bio$16.79-4.4%$15.50$5.14▼$29.46$905.13MN/A372,908 shs373,978 shsZYMEZymeworks$15.93+1.2%$13.92$9.03▼$17.70$1.20B1.27527,138 shs387,933 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNGNENeurogene0.00%-4.76%-7.36%+0.16%-54.71%STOKStoke Therapeutics0.00%+13.44%+28.83%+100.51%+62.13%UPBUpstream Bio0.00%-12.02%-7.18%+57.30%+1,756,999,900.00%ZYMEZymeworks0.00%+4.58%+9.61%+24.43%+25.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNGNENeurogene$17.45-8.2%$20.70$6.88▼$74.49$249.01M1.58219,609 shs97,415 shsSTOKStoke Therapeutics$23.40-0.3%$16.05$5.35▼$24.60$1.28B1.14815,857 shs854,185 shsUPBUpstream Bio$16.79-4.4%$15.50$5.14▼$29.46$905.13MN/A372,908 shs373,978 shsZYMEZymeworks$15.93+1.2%$13.92$9.03▼$17.70$1.20B1.27527,138 shs387,933 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNGNENeurogene0.00%-4.76%-7.36%+0.16%-54.71%STOKStoke Therapeutics0.00%+13.44%+28.83%+100.51%+62.13%UPBUpstream Bio0.00%-12.02%-7.18%+57.30%+1,756,999,900.00%ZYMEZymeworks0.00%+4.58%+9.61%+24.43%+25.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNGNENeurogene 2.75Moderate Buy$46.17164.57% UpsideSTOKStoke Therapeutics 3.22Buy$25.579.28% UpsideUPBUpstream Bio 3.00Buy$56.50236.51% UpsideZYMEZymeworks 2.90Moderate Buy$21.4334.52% UpsideCurrent Analyst Ratings BreakdownLatest NGNE, STOK, ZYME, and UPB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025STOKStoke TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$28.008/13/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/13/2025STOKStoke TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$16.00 ➝ $22.008/11/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $22.007/18/2025STOKStoke TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.007/3/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$13.007/1/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.006/17/2025NGNENeurogeneCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNGNENeurogene$930K267.75N/AN/A$20.89 per share0.84STOKStoke Therapeutics$36.56M35.07N/AN/A$4.32 per share5.42UPBUpstream Bio$2.72M332.40N/AN/A$8.77 per share1.91ZYMEZymeworks$122.87M9.75N/AN/A$6.63 per share2.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNGNENeurogene-$75.14M-$4.31N/AN/AN/AN/A-33.33%-30.34%11/17/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.8527.53N/AN/A26.25%18.32%15.48%11/4/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/A-3,836.58%-35.90%-26.26%11/6/2025 (Estimated)ZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)Latest NGNE, STOK, ZYME, and UPB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025STOKStoke Therapeutics-$0.57-$0.40+$0.17-$0.40$31.51 million$13.82 million8/11/2025Q2 2025NGNENeurogene-$1.15-$1.05+$0.10-$1.05N/AN/A8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 million8/6/2025Q2 2025UPBUpstream Bio-$0.61-$0.74-$0.13-$0.74$0.32 million$0.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNGNENeurogeneN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNGNENeurogeneN/A18.0718.07STOKStoke TherapeuticsN/A6.986.98UPBUpstream BioN/A38.2738.27ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNGNENeurogene52.37%STOKStoke TherapeuticsN/AUPBUpstream BioN/AZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipNGNENeurogene9.92%STOKStoke Therapeutics9.50%UPBUpstream Bio13.56%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNGNENeurogene9014.27 million12.86 millionOptionableSTOKStoke Therapeutics10054.80 million49.59 millionOptionableUPBUpstream Bio3853.91 million46.60 millionN/AZYMEZymeworks46075.17 million67.56 millionOptionableNGNE, STOK, ZYME, and UPB HeadlinesRecent News About These CompaniesBrokers Set Expectations for Zymeworks FY2025 EarningsSeptember 7, 2025 | marketbeat.comEcoR1 Capital LLC Purchases 2,231,469 Shares of Zymeworks Inc. $ZYMESeptember 6, 2025 | marketbeat.comTrexquant Investment LP Has $2.63 Million Stake in Zymeworks Inc. $ZYMESeptember 6, 2025 | marketbeat.comBloom Burton Comments on Zymeworks FY2025 EarningsSeptember 6, 2025 | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 5, 2025 | marketbeat.comZymeworks (NYSE:ZYME) Shares Gap Down - What's Next?September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Acquires New Position in Zymeworks Inc. $ZYMESeptember 4, 2025 | marketbeat.comZymeworks Inc. $ZYME Stake Reduced by Redmile Group LLCSeptember 4, 2025 | marketbeat.comZymeworks Inc. $ZYME Shares Acquired by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comHealth Sector Innovations: From Blood Thinners to Bird Flu OutbreaksSeptember 3, 2025 | devdiscourse.comDZymeworks: Despite T-Cell Engager Setback, ADC Candidates Press OnSeptember 2, 2025 | seekingalpha.comZymeworks drops clinical-stage T-cell engager after assessing benefit-risk profileSeptember 2, 2025 | fiercebiotech.comFZymeworks halts development of cancer drug after trial setbackSeptember 2, 2025 | reuters.comZymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell EngagerSeptember 2, 2025 | globenewswire.comWellington Management Group LLP Reduces Stock Holdings in Zymeworks Inc. $ZYMESeptember 2, 2025 | marketbeat.comNuveen LLC Acquires Shares of 198,812 Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comVanguard Group Inc. Decreases Stock Position in Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Zymeworks Inc. $ZYMEAugust 31, 2025 | marketbeat.comWalleye Capital LLC Has $2.95 Million Stake in Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comAlphaQuest LLC Purchases 28,868 Shares of Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comZymeworks Reports Q2 Results and FDA ClearanceAugust 19, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNGNE, STOK, ZYME, and UPB Company DescriptionsNeurogene NASDAQ:NGNE$17.45 -1.55 (-8.16%) Closing price 04:00 PM EasternExtended Trading$17.48 +0.03 (+0.14%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Stoke Therapeutics NASDAQ:STOK$23.40 -0.06 (-0.26%) Closing price 04:00 PM EasternExtended Trading$23.74 +0.35 (+1.47%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Upstream Bio NASDAQ:UPB$16.79 -0.78 (-4.44%) Closing price 04:00 PM EasternExtended Trading$17.03 +0.24 (+1.43%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.Zymeworks NYSE:ZYME$15.93 +0.19 (+1.21%) Closing price 04:00 PM EasternExtended Trading$15.82 -0.12 (-0.72%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
